Abstract
Peripheral T cell lymphoma (PTCL) is a group of heterogeneous lymphomas with very poor prognosis. Abnormal genes and molecular biology alterations are significant factors in the occurrence and development of PTCL. Currently, therapies of PTCL, based on chemotherapy regimens for aggressive B cell lymphomas, have resulted in insufficient outcomes. As a novel subject related to gene expression and regulation, epigenetics provides an innovative thought for studying on pathogenesis, clinical diagnosis and therapy of PTCL. Meanwhile, numerous novel epigenetic target-drugs and combinations have been developed continually. Therefore, epigenetic regulation offers a new breakthrough for diagnosis and therapy of PTCL. In this review, the mechanism of epigenetic study and application prospect of new epigenetic target-drugs therapies for PTCL are summarized. Key words: Lymphoma, T-cell, peripheral; Epigenetics; Drug therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
